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ABSTRACT 
Platinum is nowadays one of the best and widely used antitumor agents in 
cancer chemotherapy. The numerous performances reported by many 
previous researchers for this metal in the fight against several malignancies 
led to the synthesis of many platinum complexes. However, the clinical 
responses related to these complexes led to the development of non-platinum 
compounds with metal ions which exhibit antitumor activity. Ferrocene is one 
of them, owing the high consideration inter alia to its environmental oxidore-
ductive behavior. Methotrexate is another clinically used anticancer drug 
worthy to be mentioned.  With a structure very close to that of folic acid,   
differing from it by an amine function and a methyl group, respectively, 
instead of an hydrogen and an hydroxyl group on the folate, methotrexate has 
been considered as an antagonist of folic acid by its mechanism of action in 
the biological environment.  It has, together with platinum and non-platinum 
complexes, shown notorious side-effects by fighting both normal and 
abnormal cells despite their antineoplastic potency. This is the reason why a 
drug delivery system is considered as a tool to improve metal complexes and 
other drugs selectivity for cancer cells.   The strategy of enhancing the 
potency of non-polymeric chemically, physically, or biologically active 
compounds through the expediency of binding such compounds to a 
polymeric carrier has revolutioned numerous technologies. In the present 
thesis is demonstrated the synthesis of several water-soluble macromolecular 
drug carriers intended for biomedical applications, and the anchoring of 
platinum to ferrocene-containing antineoplastic agents on one side, then to 
methotrexate-containing antineoplastic agents on the other side, resulting in a 
co-conjugate or a conjugate bearing two different drugs on a single carrier. 
This multidrug anchoring offers the advantage to exploit the potency of two 
different drugs on a single polymeric structure, each drug having its own 
pharmacokinetic path. Platinum is the common drug, while ferrocene and 
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methotrexate are the various co-drugs. This order of having the platinum 
imparted to the polymeric carrier after the two drugs above mentioned  were 
adopted in obedience to the strategy of having the most synthetically 
demanding drug incorporated in the carrier before the least one. Anchoring of 
the three drugs to polymeric structures was achieved in aqueous 
environment.  Methotrexate (MTX) and ferrocene (Fc) binding were achieved 
via HBTU as coupling agent. In all cases, more or less, but very close to, 
100% drug loading could be achieved under careful control of experimental 
conditions. The water-soluble polymeric carriers used are 
copolyaspartamides, prepared by an aminolytic ring-opening process of 
polysuccinimide, and copoly(amidoamines) obtained by Michael polyaddition 
of methylenebisacrylamide (MBA). These polymers were designed to bear 
amine, hydroxyl or carboxylic acid functional groups in their structure, either 
as part of the main chain or side chain. The functional groups herein 
mentioned are important for the coupling of the chemically modified drug 
species.  Exploratory in-vitro biological studies are discussed, as the co-
conjugation of the metallic antineoplastic drug, ferrocene and the antifolate 
methotrexate, each with the metallic drug platinum, is performed. The results 
of these preliminary tests show that polymer-drug conjugates and co-
conjugates can play a role in future cancer therapy. 
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